Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMREQCF)

• Drug Name: CAR-T Cells targeting EpCAM Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colon cancer	2B90.Z	Phase 1/2	[1]
Esophageal cancer	2B70	Phase 1/2	[1]
Gastric adenocarcinoma	2B72	Phase 1/2	[1]
Hepatocellular carcinoma	2C12.02	Phase 1/2	[1]
Pancreatic cancer	2C10	Phase 1/2	[1]
Prostate cancer	2C82.0	Phase 1/2	[1]
Metastatic cancer	2D50-2E2Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMREQCF

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor-associated calcium signal transducer 1 (EPCAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vicineum	DMLO0KD	Bladder cancer	2C94	Phase 3	[3]
VB4-845	DMGKRAJ	Head and neck cancer	2D42	Phase 2/3	[4]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
A-337	DMRWTFG	Non-small-cell lung cancer	2C25.Y	Phase 1	[6]
CAR-T cells recognizing EpCAM	DMC7Y5F	Breast cancer	2C60-2C65	Phase 1	[7]
ING-1	DM5WCBM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Citatuzumab bogatox	DMRJF2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
EPCAM-targeted CAR-T cells	DMV6RMB	Gastric adenocarcinoma	2B72	Clinical trial	[10]
IGN-101	DMOG1LX	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[11]
Vicineum	DMLO0KD	Bladder cancer	2C94	Phase 3	[3]
VB4-845	DMGKRAJ	Head and neck cancer	2D42	Phase 2/3	[4]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
A-337	DMRWTFG	Non-small-cell lung cancer	2C25.Y	Phase 1	[6]
CAR-T cells recognizing EpCAM	DMC7Y5F	Breast cancer	2C60-2C65	Phase 1	[7]
ING-1	DM5WCBM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Citatuzumab bogatox	DMRJF2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
EPCAM-targeted CAR-T cells	DMV6RMB	Gastric adenocarcinoma	2B72	Clinical trial	[10]
IGN-101	DMOG1LX	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor-associated calcium signal transducer 1 (EPCAM)	TTZ8WH4	EPCAM_HUMAN	CAR-T-Cell-Therapy	[2]

References

• [1] ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
• [2] ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
• [3] Clinical pipeline report, company report or official report of Sesen Bio.
• [4] A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249.
• [5] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
• [6] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [7] ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
• [8] ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65.
• [9] Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92.
• [10] ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
• [11] Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. Curr Opin Mol Ther. 2006 Aug;8(4):358-65.